Skip to main content
SpringerLink
Log in

Matrix metalloproteinase inhibitors in the treatment of cancer

  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases are a family of zinc-containing proteolytic enzymes that break down extracellular matrix proteins in normal physiological processes such as embryogenesis, tissue growth, and wound healing. The family includes collagenases, gelatinases, stromelysins and metalloelastase. Observational and experimental data from studies of human malignancy indicate that these proteinases are induced by the tumour in order to reconstruct adjacent normal tissue to allow neovascularisation, tumour growth and spread. Tumours have been shown to overexpress certain matrix metalloproteinases relative to normal tissue and recent studies have shown an association between high levels of expression and poor prognosis. A large series of synthetic inhibitors have been developed using the structure of a principal substrate, collagen. The inhibitors contain a chemical group that binds the zinc atom in the active site of the metalloenzyme. Inhibition is specific for the known matrix metalloproteinase family and is reversible. Studies with these inhibitors and native tissue inhibitors of matrix metalloproteinases have shown that they can prevent the growth and spread of experimental tumours. In other studies, the inhibitors have been shown to be directly anti-angiogenic. Synthetic matrix metalloproteinase inhibitors have now reached the stage of clinical testing and preliminary results indicate that the compounds may be effective in slowing tumour growth. Trials currently underway should reveal whether this approach will become a standard part of anti-neoplastic therapy in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Taylor, A.C., Levy, B.M. and Simpson, J.W. (1970) Collagenolytic activity of sarcoma tissues in culture.Nature 228, 366–7.

    Article  PubMed  CAS  Google Scholar 

  2. Dresden, M.H., Heilman, S.A. and Schmidt, J.D. (1972) Collagenolytic enzymes in human neoplasms.Cancer Res. 32, 993–6.

    PubMed  CAS  Google Scholar 

  3. Yamanishi, Y., Maeyens, E., Dabbous, M.K., Ohyama, H. and Hashimoto, K. (1973) Collagenolytic activity in malignant melanoma.Cancer Res. 33, 2790–801.

    PubMed  Google Scholar 

  4. Liotta, L.A., Tryggvason, S., Garbisa, S., Hart, I., Foltz, C.M. and Shafie, S. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen.Nature 284, 67–8.

    Article  PubMed  CAS  Google Scholar 

  5. Liotta, L.A., Tryggvason, K., Garbisa, S., Robey, P.G. and Abe, S. (1981) Partial purification and characterisation of a neutral protease which cleaves type IV collagen.Biochemistry 20, 100–4.

    Article  PubMed  CAS  Google Scholar 

  6. Wilhelm, S.C, Eisen, A.Z., Teter, M., Clark, S.D., Kronberger, A. and Goldberg, G. (1986) Human fibroblast collagenase: glycosylation and tissue-specific levels of enzyme synthesis.Proc. Natl. Acad. Sci. USA 83, 3756–60.

    Article  PubMed  CAS  Google Scholar 

  7. Hasty, K.A., Pourmotabbed, T.F., Goldberg, G.I., Thompson, J.P., Spinella, D.G., Stevens, R.M. and Mainardi, C.L. (1990) Human neutrophil collagenase; a distinct gene product with homology to other matrix metalloproteinases.J. Biol Chem. 265, 11421–4.

    PubMed  CAS  Google Scholar 

  8. Collier, I.E., Wilhelm, S.M., Eisen, A.Z., Manner, B.L., Grant, G.A., Seltzer, J.L., Kronberger, A., He, C., Bauer, E.A. and Goldberg, G.I. (1988) H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metallo-protease capable of degrading basement membrane collagen.J. Biol Chem. 263, 6579–87.

    PubMed  CAS  Google Scholar 

  9. Wilhelm, S.M., Collier, I.E., Manner, B.L., Eisen, A.Z., Grant, G.A. and Goldberg, G.I. (1989) SV40-transformed human lung fibroblasts secrete a 92-kDa Type IV collagenase which is identical to that secreted by normal human macrophages.J. Biol. Chem. 264, 17213–21.

    PubMed  CAS  Google Scholar 

  10. Senior, R.M., Griffin, G.L., Fliszar, C.J., Shapiro, S.D., Goldberg, G.I. and Welgus, H.G. (1991) Human 92- and 72-kilodalton type IV collagenases are elastases.J. Biol. Chem. 266, 7870–5.

    PubMed  CAS  Google Scholar 

  11. Wilhelm, S.M., Collier, I.E., Kronberger, A., Eisen, A.Z., Manner, B.L., Grant, G.G., Bauer, E.A. and Goldberg, G.I. (1987) Human skin fibroblast stromelysin: Structure, glycosylation, substrate specificity, and differential expression in normal and tumourigenic cells.Proc. Natl. Acad. Sci. USA 84, 6725–9.

    Article  PubMed  CAS  Google Scholar 

  12. Muller, D., Quantin, B., Gesnel, M.C., Millon-Collard, R., Abecassis, J. and Breathnach, R. (1988) The collagenase gene family in humans consists of at least four members.Biochem. J. 253, 187–92.

    PubMed  CAS  Google Scholar 

  13. Basset, P., Bellocq, J.P., Wolf, C, Stoll, I., Hutin, P., Limacher, J.M., Podhajcer, O.L., Chenard, M.P., Rio, M.C. and Chambon, P. (1990) A novel metalloproteinase gene specifically expressed in stromal cell of breast carcinomas.Nature 348, 699–704.

    Article  PubMed  CAS  Google Scholar 

  14. Pei, D., Majmudar, G. and Weiss, S.J. (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3.J. Biol. Chem. 269, 25849–55.

    PubMed  CAS  Google Scholar 

  15. Quantin, B., Murphy, G. and Breathnach, R. (1989) Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members.Biochemistry 28, 5325–34.

    Article  Google Scholar 

  16. Shapiro, S.D. Kobayashi, D.K. and Ley, T.J. (1993) Cloning and characterisation of a unique elastolytic metalloproteinase produced by human alveolar macrophages.J. Biol. Chem. 268, 23824–9.

    PubMed  CAS  Google Scholar 

  17. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E. and Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells.Nature 370, 61–5.

    Article  PubMed  CAS  Google Scholar 

  18. Will, H. and Hinzmann, B. (1995) cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment.Eur. J. Biochem. 231, 602–8.

    Article  PubMed  CAS  Google Scholar 

  19. Takino, T., Sato, H., Shinagawa, A. and Seiki, M. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family.J. Biol. Chem. 270, 23013–20.

    Article  PubMed  CAS  Google Scholar 

  20. Puente, X.S., Pendas, A.M., Llano, E., Velasco, G. and Lopez-Otin, C. (1996) Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma.Cancer Res. 56, 944–9.

    PubMed  CAS  Google Scholar 

  21. Strongin, A., Collier, I., Bannikov, G., Marmer, B.L., Grant, G.A. and Goldberg, G.I. (1995) Mechanism of cell surface activation of 72 kDa type IV collagenase.J. Biol. Chem. 270, 5331–8.

    Article  PubMed  CAS  Google Scholar 

  22. Cossins, J., Dudgeon, T.J., Catlin, G., Gearing, A.J.H. and Clements, J.M. (1996) Identification of MMP-18, a putative novel human matrix metalloproteinase.Biochem. Biophys. Res. Commun. 228, 494–8.

    Article  PubMed  CAS  Google Scholar 

  23. Docherty, A.J.P., Lyons, A., Smith, B.J., Wright, E.M., Stephens, P.E. and Harris, T.J.R. (1985) Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity.Nature 318, 66–9.

    Article  PubMed  CAS  Google Scholar 

  24. Stetler-Stevenson, W.G., Krutzsch, H.C. and Liotta, L.A. (1989) Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family.J. Biol Chem. 264, 17374–8.

    PubMed  CAS  Google Scholar 

  25. Apte, S.S., Mattel, M.G. and Olsen, B.R. (1994) Cloning of the cDNA encoding human tissue inhibitor of metallo-proteinases-3 (TIMP-3) and the mapping of the TIMP-3 gene to chromosome 22.Genomics 19, 86–90.

    Article  PubMed  CAS  Google Scholar 

  26. Greene, J., Wang, M.S., Liu, Y.L.E., Raymond, L.A., Rosen, C. and Shi, Y.N.E. (1996) Molecular cloning and characterisation of human tissue inhibitor of metalloproteinase 4.J. Biol Chem. 271, 30375–80.

    Article  PubMed  CAS  Google Scholar 

  27. Kleiner, D.J. and Stetler-Stevenson, W.G. (1993) Structural biochemistry and activation of matrix metalloproteinases.Curr. Op. Cell Biol. 5, 891–7.

    Article  PubMed  CAS  Google Scholar 

  28. Powell, W.C. and Matrisian, L.M. (1996) Complex roles of matrix metalloproteinases in tumour progression.Curr. Top. Microbiol. Immun. 213, 1–21.

    CAS  Google Scholar 

  29. van der Stappen, J.W.J., Hendriks, T. and Wobbes, T. (1990) Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumours.Int. J. Cancer 45, 1071–8.

    Article  PubMed  Google Scholar 

  30. Hewitt, R.E., Leach, I.H., Powe, D.G., Clark, I.M., Cawston, T.E. and Turner, D.R. (1991) Distribution of collagenase and tissue inhibitor metalloproteinases (TIMP) in colorectal tumours.Int. J. Cancer 49, 666–72.

    Article  PubMed  CAS  Google Scholar 

  31. Murray, G.I., Duncan, M.E., O’Neil, P., Melvin, W.T. and Fothergill, J.E. (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.Nature Med. 2, 461–2.

    Article  PubMed  CAS  Google Scholar 

  32. Newell, K.J., Witty, J.P., Rodgers, W.H. and Matrisian, L.M. (1994) Expression and localisation of matrix-degrading metalloproteinases during colorectal tumourigenesis.Mol. Carcin. 10, 199–206.

    Article  CAS  Google Scholar 

  33. Gallegos, N.C., Smales, C, Savage, F.G., Hembry, R.M. and Boulos, P.B. (1995) The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.Surg. Oncol. 4, 21–9.

    Article  PubMed  CAS  Google Scholar 

  34. Levy, A.T., Cioce, V., Sobel, M.E., Garbisa, S., Grigioni, W.F., Liotta, L.A. and Stetler-Stevenson, W.G. (1991) Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma.Cancer Res. 51, 439–44.

    PubMed  CAS  Google Scholar 

  35. Liabakk, N-B., Talbot, L, Smith, R.A., Wilkinson, K. and Balkwill, F. (1996) Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer.Cancer Res. 56, 190–6.

    PubMed  CAS  Google Scholar 

  36. Brown, P.D., Bloxidge, R.E., Stuart, N.S.A., Gatter, K.C. and Carmichael, J. (1993) Correlation between expression of activated 72-kDa gelatinase and tumour spread in non-small cell lung carcinoma.J. Natl. Cancer Inst 85, 574–8.

    Article  PubMed  CAS  Google Scholar 

  37. Emmert-Buck, M.R., Roth, M.J., Zhuang, Z., Campo, E., Rozhin, J., Sloane, B.F., Liotta, L.A. and Stetler-Stevenson, W.G. (1994) Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon-cancer samples.Am. J. Pathol. 145, 1285–90.

    PubMed  CAS  Google Scholar 

  38. Zeng, Z.S. and Guillem, J.G. (1995) Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases.Br. J. Cancer 72, 575–82.

    PubMed  CAS  Google Scholar 

  39. Zeng, Z.S., Huang, Y., Cohen, A.M. and Guillem, J.G. (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9.J. Clin. Oncol. 14, 3133–40.

    PubMed  CAS  Google Scholar 

  40. Zucker, S., Lysik, R.M., Zarrabi, M.H. and Moll, U. (1993) Mr92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.Cancer Res. 53,140–6.

    PubMed  CAS  Google Scholar 

  41. Yoshimoto, M., Itoh, F., Yamamoto, H., Hinoda, Y., Imai, K. and Yachi, A. (1993) Expression of MMP-7 (Pump-1) mRNA in human colorectal cancers.Int. J. Cancer 54, 614–8.

    Article  PubMed  CAS  Google Scholar 

  42. Mori, M., Barnard, G.F., Mimori, K., Ueo, H., Akiyoshi, T. and Sugimachi, K. (1995) Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas.Cancer 75, 1516–9.

    Article  PubMed  CAS  Google Scholar 

  43. Ishikawa, T., Ichikawa, Y., Mitsuhashi, M., Momiyama, N., Chishima, T., Tanaka, K., Yamaoka, H., Miyazakic, K., Nagashima, Y., Akitaya, T. and Shimada, H. (1996) Matrilysin is associated with progression of colorectal tumor.Cancer Lett. 107, 5–10.

    Article  PubMed  CAS  Google Scholar 

  44. Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P. and Gespach, C. (1995) Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes.Int. J. Cancer 64, 70–5.

    Article  PubMed  CAS  Google Scholar 

  45. Zeng, Z., Cohen, A.M., Zhang, Z., Stetler-Stevenson, W.G. and Guillem, J.G. (1995) Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases.Clin. Cancer Res. 1, 899–906.

    PubMed  CAS  Google Scholar 

  46. Kossakowska, A.E., Huchcroft, S.A., Urbanski, S.J. and Edwards D.R. (1996) Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans.Br. J. Cancer 73, 1401–8.

    PubMed  CAS  Google Scholar 

  47. Yoshiji, H., Gomez, D.E. and Thorgeirsson, U.P. (1996) Enhanced RNA expression of tissue inhibitor of metallo-proteinases-1 (TIMP-1) in human breast cancer.Int J. Cancer 69, 131–4.

    Article  PubMed  CAS  Google Scholar 

  48. Grignon, D.J., Sakr, W., Toth, M., Ravery, V., Angulo, J., Shamsa, F., Pontes, J.E., Crissman, J.C. and Fridman, R. (1996) High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.Cancer Res. 56, 1654–9.

    PubMed  CAS  Google Scholar 

  49. Alderson, M.R., Hamlin, I. and Staunton, M.D. (1971) The relative significance of prognostic factors in breast carcinoma.Br. J. Cancer 25, 646–56.

    PubMed  CAS  Google Scholar 

  50. Anastassiades, O.T. and Pryce, P.M. (1974) Fibrosis as an indication of time in infiltrating breast cancer and its importance in prognosis.Br. J. Cancer 29, 232–9.

    PubMed  CAS  Google Scholar 

  51. Carlomagno, C., Perrone, F., Lauria, R., De Laurentiis, M., Gallo, C., Morabito, A, Pettinato, G., Panico, L., Bellelii, T., Apicella, A., Petrella, G., Bianco, A.R. and De Placido, S. (1995) Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer.Oncology 52, 272–7.

    Article  PubMed  CAS  Google Scholar 

  52. Parham, D.M., Hagen, N. and Brown, R.A. (1992) Simplified method of grading primary carcinomas of the breast.J. Clin. Pathol. 45, 517–20.

    Article  PubMed  CAS  Google Scholar 

  53. Takei, H., Iino, Y., Horiguchi, J. and Yakoe, T. (1995) Immunohistochemical fibronectin staining pattern and prognosis in invasive breast carcinoma.Oncology 52, 106–11.

    PubMed  CAS  Google Scholar 

  54. Halvorsen, T.B. and Seim, E. (1989) Association between invasiveness, inflammatory cell reaction, desmoplasia and survival in colorectal cancer.J. Clin. Pathol. 42, 162–6.

    Article  PubMed  CAS  Google Scholar 

  55. Yamauchi, H., Kikuchi, Y. and Kakizaki, K. (1995) Relation between the stromal volume and liver metastasis in ductal cell carcinoma of the pancreas.Tohoku J. Exp. Med. 177, 179–81.

    Article  PubMed  CAS  Google Scholar 

  56. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J. and Harris, A.L. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.Cancer Res. 56, 4625–9.

    PubMed  CAS  Google Scholar 

  57. Pupa, S.M., Bufalino, R., Invernizzi, A.M., Andreola, S., Rilke, F., Lombardi, L., Colnaghi, M.L. and Menard, S. (1996) Macrophage infiltrate and prognosis in c-erB-2-overexpressing breast carcinomas.J. Clin. Oncol. 14, 85–94.

    PubMed  CAS  Google Scholar 

  58. Beckett, R.P., Davidson, A.H., Drummond, A.H., Huxley, P. and Whittaker, M. (1996) Recent advances in matrix metalloproteinase inhibitor research.Drug. Dev. Today 1, 16–26.

    Article  CAS  Google Scholar 

  59. Gearing, A.J.H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A.H., Drummond, A.H., Galloway, W.A., Gilbert, R., Gordon, J.L., Leber, T.M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L.M. and Woolley, K. (1994) Processing of tumour necrosis factor-7 precursor by metalloproteinases.Nature 370, 555–7.

    Article  PubMed  CAS  Google Scholar 

  60. Reich, R., Thompson, E.W., Iwamoto, Y., Martin, G.R., Deason, J.R., Fuller, G.C. and Miskin, R. (1988) Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells.Cancer Res. 48, 3307–12.

    PubMed  CAS  Google Scholar 

  61. Schultz, R.M., Silberman, S., Persky, B., Bajkowski, A.S. and Carmichael, D.F. (1988) Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells.Cancer Res. 48, 5539–45.

    PubMed  CAS  Google Scholar 

  62. Eccles, S.A., Box, G.M., Court, W.J., Bone, E.A., Thomas, W. and Brown, P.D. (1996) Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94).Cancer Res. 56, 2815–22.

    PubMed  CAS  Google Scholar 

  63. Sledge, G.W., Qulali, M, Goulet R., Bone, E.A. and Fife, R. (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.J. Natl. Cancer Res. 87, 1546–50.

    Article  CAS  Google Scholar 

  64. DeClerck, Y.A., Perez, N., Shimada, H., Boone, T.C., Langley, K.E. and Taylor, S.M. (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases.Cancer Res. 52, 701–8.

    PubMed  CAS  Google Scholar 

  65. Johnson, M.D., Kim, H.R., Chesler, L., Tsao-Wu, G., Bouck, N. and Polverini, P.J. (1994) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.J. Cell Physiol. 160, 194–202.

    Article  PubMed  CAS  Google Scholar 

  66. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. and Giavazzi, R. (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases.J. Natl. Cancer Inst 87, 293–8.

    Article  PubMed  CAS  Google Scholar 

  67. Anderson, I.C., Shipp, M.A., Docherty, A.J.P. and Teicher, B.A. (1996) Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma.Cancer Res. 56, 715–20.

    CAS  Google Scholar 

  68. Beckett, R.P. (1996) Recent advances in the field of matrix metalloproteinase inhibitors (patent update).Exp. Opin. Ther. Patents 6, 1305–15.

    Article  CAS  Google Scholar 

  69. Galardy, R.E., Cassabone, M.E., Giese, C, Gilbert, J.H., Lapierre, F., Lopez, H.et al. (1994) Low molecular weight inhibitors in corneal ulceration.Ann. N.Y. Acad. Sci. 732, 315–23.

    Article  PubMed  CAS  Google Scholar 

  70. Macaulay, V.M., O’Byrne, K.J., Saunders, M.P., Salisbury, A., Long, L., Gleeson, F., Ganesan, T.S., Harris, A.L. and Talbot, D.C. (1995) Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions.Br. J. Cancer 71, 11 (Abstract).

    Google Scholar 

  71. Primrose, J., Bleiberg, H., Daniel, F., Johnson, P., Mansi, J., Neoptolemos, J., Seymour, M. and Van Belle, S. (1996) A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer.Ann. Oncol. 7, 35 (Abstract).

    Google Scholar 

  72. Poole, C, Adams, M., Barley, V., Graham, J., Kerr, D., Louviaux, I., Perren, T., Piccart, M. and Thomas, H. (1996) A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer.Ann. Oncol 7, 68 (Abstract).

    Google Scholar 

  73. Millar, A. and Brown, P. (1996) 360 patient meta-analysis of studies of marimastat, a novel matrix metalloproteinase inhibitor.Ann. Oncol. 7, 123 (Abstract).

    Google Scholar 

  74. Parsons, S.L., Watson, S.A., Griffin, N.R. and Steele, R.J.C. (1996) An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer.Ann. Oncol. 7, 47 (Abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Research, British Biotech Pharmaceuticals Ltd, Watlington Road, OX4 5LY, Oxford, UK

    Peter D. Brown

Authors
  1. Peter D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, P.D. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 14, 1–10 (1997). https://doi.org/10.1007/BF02990939

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02990939

Keywords

Search

Navigation